- Home
- KNSA
as 11-21-2025 3:31pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $51.33 | AVG Volume (30 days): | 461.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.82 - $42.93 | Next Earning Date: | 10-28-2025 |
| Revenue: | $597,973,000 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 62.63% | Revenue Growth (next year): | 29.93% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 17 '25 | Sell | $40.69 | 12,470 | $514,224.10 | 22,714 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Nov 12 '25 | Sell | $40.94 | 19,900 | $814,706.00 | 31,086 | |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Oct 31 '25 | Sell | $37.14 | 82,542 | $3,065,609.88 | 61,324 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Oct 28 '25 | Sell | $41.00 | 100 | $4,100.00 | 31,086 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 22 '25 | Sell | $38.83 | 97,390 | $3,781,653.70 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 21 '25 | Sell | $38.77 | 39,331 | $1,524,862.87 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 20 '25 | Sell | $39.07 | 121,248 | $4,717,015.02 | 111,794 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Oct 20 '25 | Sell | $39.02 | 50,490 | $1,962,781.45 | 27,046 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Oct 14 '25 | Sell | $37.82 | 12,368 | $465,843.22 | 22,714 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 29 '25 | Sell | $38.33 | 42,000 | $1,609,860.00 | 22,714 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation
GlobeNewswire
a month ago
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Zacks
a month ago
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
Zacks
2 months ago
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Zacks
2 months ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Zacks
2 months ago
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,506,278, According to a Recent SEC Filing
MT Newswires
3 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.